PubMed Health⌕ Search

PubMed · 16553368

Fluorobenzene-nucleobase interactions: hydrogen bonding or pi-stacking?

Abstract

Studies on modified DNA oligomers and polymerase reactions have previously demonstrated that canonical nucleobases can exhibit stable and even selective pairing with shape-complementary fluorobenzene nucleotides. Because of the fluorination of the pairing edges, hydrogen bonds are believed to be absent, and the local DNA stability has been attributed to pi-stacking and shape complementarity. Using two-color resonant two-photon ionization and fluorescence emission spectroscopies, we show here that supersonically cooled complexes of the nucleobase analogue 2-pyridone with seven substituted fluorobenzenes (1-fluorobenzene, 1,2- and 1,4-difluorobenzene, 1,3,5- and 1,2,3-trifluorobenzene, 1,2,4,5- and 1,2,3,4-tetrafluorobenzene) are hydrogen-bonded and not pi-stacked. The S1 <--> S0 vibronic spectra show intermolecular vibrational frequencies that are characteristic for doubly hydrogen bonded complexes. The bands shift to the blue with increasing hydrogen-bond strength; the measured spectral blue shifts deltanu are in excellent agreement with the ab initio calculated shifts. The spectral shifts are also linearly correlated with the calculated hydrogen-bond dissociation energies D0, published in a companion paper (Frey, J. A.; Leist, R.; Leutwyler, S. J. Phys. Chem. A 2006, 110, 4188). This correlation allows us to reliably estimate the ground-state dissociation energies as D0 approximately 6 kcal/mol of the 2-pyridone.fluorobenzene complexes from the observed spectral shifts.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Roman Leist, Jann A Frey, Samuel Leutwyler. 2006-03-30. Fluorobenzene-nucleobase interactions: hydrogen bonding or pi-stacking?. https://doi.org/10.1021/jp057100h

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Rosuvastatin: an independent analysis of risks and benefits.

BACKGROUND: Although the effectiveness of statins is well established, analyses of spontaneous adverse event reports have recently questioned the safety of rosuvastatin. METHODS AND RESULTS: We evaluated the risks and benefits of rosuvastatin and compared it with other statins presently on the market. Information was obtained from a search of medical and scientific literature that produced 3001 entries, of which 591 publications containing particularly relevant data were identified, and from the US Food and Drug Administration (FDA) Adverse Events Reporting System (AERS) and Spontaneous Reporting System through June 30, 2004. For the AERS data and to control for overreporting in the first postmarketing year and the effect on reporting due to the withdrawal of cerivastatin in 2001, we used the rate of a given adverse event among all adverse events as a measure of risk. We found that adverse effects of rosuvastatin in skeletal muscle, liver, and kidney function did not substantially differ in frequency from those reported for those of other statins in the market in 2004, except for the uncommon development of a mild form of presumably "tubular" proteinuria at doses of 40 mg/day or greater. In contrast, cerivastatin had significantly higher rates of myopathy and rhabdomyolysis than rosuvastatin's, but there was no additional effect on renal failure beyond that mediated through rhabdomyolysis. From our literature review, we found that rosuvastatin reduces abnormal lipids on a milligram-per-milligram comparison more than atorvastatin. CONCLUSION: We conclude that rosuvastatin at approved doses incurs no greater risk for adverse events than other marketed statins, except for a mild form of tubular proteinuria when doses at or above the maximum recommended levels (> or = 40 mg/day) were administered. Its risk-benefit ratio is acceptable when compared with other statins on the market in 2006.

Fluorobenzenes↗

Force field calculations for 2-amino-5-chloro- and 2-amino-5-bromo-benzotrifluorides.

Force field calculations have been carried out for 2-amino-5-chloro- and 2-amino-5-bromo-benzotrifluorides using the earlier (Ref. of this article) reported IR and Raman spectra. As the frequencies of the corresponding modes for the C-Br and the C-Cl groups do not differ widely the two molecules are assumed to be isotopomers for the purpose of the force field calculations. The calculated and the observed frequencies match nicely for both the molecules. Consistent assignments have been proposed for the ring modes and the internal modes of the CF3 and the NH2 groups based on the potential energy distributions (PEDs), the IR and the Raman intensities and the depolarisation ratios of the Raman lines.

Fluorobenzenes↗

Short-term memory loss associated with rosuvastatin.

Memory loss and cognitive impairment have been reported in the literature in association with several 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), but we found no published case reports associated with rosuvastatin. To our knowledge, this is the first reported case of rosuvastatin-related short-term memory loss. A 53-year-old Caucasian man with hypercholesterolemia experienced memory loss after being treated with rosuvastatin 10 mg/day. He had no other concomitant conditions or drug therapies. After discontinuation of rosuvastatin, the neuropsychiatric adverse reaction resolved gradually, suggesting a probable drug association. During the following year, the patient remained free from neuropsychiatric disturbances. Clinicians should be aware of possible adverse cognitive reactions during statin therapy, including rosuvastatin.

Fluorobenzenes↗